Ceftriaxone therapy in otolaryngological and pulmonary infections.
The efficacy of ceftriaxone, 1 g given intramuscularly once daily, was evaluated in 38 patients with pneumonia (n = 11), pulmonary empyema (n = 2), bronchitis (n = 4), tonsillitis (n = 9), sinusitis (n = 7), and otitis (n = 5). Causative organisms were Streptococcus pneumoniae (n = 11), viridans type streptococcus (n = 1), Haemophilus influenzae (n = 6), group A streptococcus (n = 10), Staphylococcus aureus (n = 3), Klebsiella pneumoniae (n = 2), Pseudomonas aeruginosa (n = 1), Escherichia coli (n = 2), Proteus mirabilis (n = 1), and Proteus vulgaris (n = 1). Sterilization of infected foci was obtained in 89.4% of those treated, with clinical recovery in 86.8%. The ceftriaxone regimen was well tolerated.
F
F
Fraschini
P C
PC
Braga
M
M
Falchi
G
G
Gattei
F
F
Scaglione
G
G
Scarpazza
D
D
Esposti
D000293:Adolescent; D000328:Adult; D000368:Aged; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010031:Otitis / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014069:Tonsillitis / Q000188:drug therapy*
D002443:Ceftriaxone